Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.

Expert Review of Hematology
Pellegrino Musto, Francesco La Rocca

Abstract

Introduction: In the last few years, monoclonal antibodies have rapidly modified the therapeutic strategies for treating patients with multiple myeloma.Areas covered: In this review, the most recent literature data regarding indications for which monoclonal antibodies are currently or will be shortly approved as salvage therapies in relapsed/refractory myeloma are discussed. In particular, updated results until March 22, 2020 of antibodies directed against CD38 (daratumumab and isatuximab), SLAMF7 (elotuzumab), BCMA (GSK2857916/belantamab mafodotin), and PD-1/PD-1 L axis (nivolumab and pembrolizumab) will be analyzed in detail.Expert opinion: Monoclonal antibodies represent a new, very effective approach that will open novel and dynamic treatment scenarios for myeloma patients in the coming years. Optimal positioning and selection of different antibodies that are or will be soon available, appropriate combinations and careful evaluation of possible new toxicities should be considered in the future management of these patients.

References

Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrzej J JakubowiakKenneth C Anderson
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander M LesokhinJohn Timmerman
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chrissy H Y van Beurden-TanPieter Sonneveld
Nov 10, 2017·Blood·Niels W C J van de DonkFabio Malavasi
Jan 27, 2018·The Oncologist·Kyriaki TzoganiFrancesco Pignatti
Feb 20, 2018·Clinical Lymphoma, Myeloma & Leukemia·Meletios Athanasios DimopoulosAnnette Lam
Feb 22, 2018·Expert Review of Clinical Immunology·Kristine A FrerichsNiels W C J van de Donk
Mar 28, 2018·Expert Review of Hematology·Elena ZamagniMichele Cavo
Jul 6, 2018·British Journal of Haematology·Andrew J JohnsrudJuan C Rico
Nov 6, 2018·Expert Opinion on Biological Therapy·Francesca BonelloFrancesca Gay
Nov 8, 2018·The New England Journal of Medicine·Meletios A DimopoulosJesús San-Miguel
Dec 2, 2018·Frontiers in Immunology·Guido LancmanAjai Chari
Dec 13, 2018·Frontiers in Immunology·Stefania OlivaFrancesca Gay
Jan 30, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura MorenoBruno Paiva
Feb 28, 2019·Expert Review of Anticancer Therapy·Maria GavriatopoulouEvangelos Terpos
Mar 31, 2019·Blood Cancer Journal·Thomas MartinJoseph Mikhael

❮ Previous
Next ❯

Citations

Sep 10, 2020·Journal of Clinical Medicine·Paola StortiNicola Giuliani
May 1, 2021·International Journal of Molecular Sciences·John R Couchman
Jan 2, 2021·Blood Reviews·Joshua Richter, Santiago Thibaud
Jul 27, 2021·Frontiers in Oncology·Alessandra RomanoNicola Giuliani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.